Michael Drazer is an Assistant Professor in the Section of Hematology/Oncology at the University of Chicago. He was raised on a family farm before graduating from Indiana University with degrees in Biochemistry, Biology, and English. He earned an MD and a PhD in Human Genetics from the University of Chicago. He cares for patients with hereditary blood disorders and hereditary cancer syndromes as a member of the Hematology, Leukemia, Stem Cell Transplant/Cellular Therapy, Mesothelioma, Myeloma, and Cancer Risk programs at UChicago. He is a trainer in the Human Genetics PhD program at UChicago. He also serves as the Associate Program Director of the Physician Scientist Development Program in the Department of Medicine, where he is responsible for directing the development of physician scientists pursuing accelerated residency and fellowship training.
Outside of the lab and hospital, you can find him running long distances through the woods of the Midwest and up/down the mountains of the western United States.
Indiana University
Bloomington
BA, BS - Biochemistry; Biology; English
University of Chicago
Chicago
PhD - Human Genetics
University of Chicago
Chicago
MD - Medicine
University of Chicago
Chicago
Residency - Internal Medicine
University of Chicago
Chicago
Fellowship - Hematology/Oncology
Predisposition to hematopoietic malignancies by deleterious germline CHEK2 variants.
Predisposition to hematopoietic malignancies by deleterious germline CHEK2 variants. Leukemia. 2025 May 07.
PMID: 40335619
ANKRD26-related Thrombocytopenia 2 with a Baseline Increase in Blasts: Implications for Clinical Surveillance.
ANKRD26-related Thrombocytopenia 2 with a Baseline Increase in Blasts: Implications for Clinical Surveillance. Blood. 2025 May 07.
PMID: 40331912
Germ line JAK2 variants and hereditary blood cancers.
Germ line JAK2 variants and hereditary blood cancers. Blood Adv. 2025 Apr 08; 9(7):1585-1586.
PMID: 40152887
Treatment of Pleural Mesothelioma: ASCO Guideline Clinical Insights.
Treatment of Pleural Mesothelioma: ASCO Guideline Clinical Insights. JCO Oncol Pract. 2025 Mar 07; OP2500035.
PMID: 40053896
Treatment of Pleural Mesothelioma: ASCO Guideline Update.
Treatment of Pleural Mesothelioma: ASCO Guideline Update. J Clin Oncol. 2025 Mar 10; 43(8):1006-1038.
PMID: 39778125
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation.
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation. Haematologica. 2024 Nov 01; 109(11):3739-3744.
PMID: 38618681
Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition.
Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition. Blood. 2024 10 24; 144(17):1765-1780.
PMID: 38991192
FLT3 Agonists and Secondary Hematopoietic Malignancies: A Potential Class Effect.
FLT3 Agonists and Secondary Hematopoietic Malignancies: A Potential Class Effect. Clin Cancer Res. 2024 Jul 15; 30(14):2857-2859.
PMID: 38652676
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms.
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood Cancer J. 2024 06 18; 14(1):99.
PMID: 38890297
ASO Author Reflections: Venous Thromboembolism in Peritoneal Mesothelioma.
ASO Author Reflections: Venous Thromboembolism in Peritoneal Mesothelioma. Ann Surg Oncol. 2024 Jun; 31(6):3785-3786.
PMID: 38502295